Carmine Therapeutics
Latest round
- Series A
Last raised
- Oct 2022
Total raised
- Undisclosed
Investors
- 4
About Carmine Therapeutics
Based in Singapore, and established in 2019, Carmine Therapeutics is a biotechnology company that focuses on R&D of the red cell extracellular vesicles genetic therapeutics. It was founded in 2019 by EVX Ventures, Professors Harvey Lodish, Minh Le and Jiahai Shi. Professor Lodish, is also one of the founder members of several successful biotech companies, such as Genzyme and Millennium Pharmaceuticals. In 2020, it aligned with Takeda Pharmaceuticals to develop non-viral gene therapies for 2 targets. Carmine Therapeutics is developing gene therapeutics, based on the red cell extracellular vesicles, which can overcome the difficulties of viral-based gene therapies for immunogenicity, and small transgene capacity, and manufacturing.
Who invested in Carmine Therapeutics
4 investors across 1 round
See all investors in Carmine Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 13, 2022
Amount
Undisclosed
Investors
Questions about Carmine Therapeutics
Who invested in Carmine Therapeutics?
Carmine Therapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Carmine Therapeutics raised?
Carmine Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Carmine Therapeutics last raise money?
Carmine Therapeutics's most recent round on record is a Series A, in Oct 2022.
What does Carmine Therapeutics do?
Based in Singapore, and established in 2019, Carmine Therapeutics is a biotechnology company that focuses on R&D of the red cell extracellular vesicles genetic therapeutics.
Where is Carmine Therapeutics headquartered?
Carmine Therapeutics is headquartered in Singapore.
Which VCs invest in companies like Carmine Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Carmine Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Carmine Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.